The Boots Company Plc

Other

David J Buttle

Daniel H Rich

Alan J Barrett

Andrew D Rowan

A pharmaceutical composition comprising purified chymopapain and a reducing agent is presented. The purified chymopapain in this composition has a specific activity against 1 mM of N-.alpha.-benzoyl-DL-arginine p-nitroanilide at 40.degree. C. and pH 6.8 of between 3,000 and 4,500 units per mg, and contains less than 0.2% each of papaya proteinase III (PPIII), papain, and papaya proteinase IV (PPIV).

Pharmaceutical composition of purified chymopapain

Chymopapain and method of purifying it on an inhibitory dipeptide

A cysteine proteinase characterized in that it is immunologically distinct, has a molecular mass of about 25,000 and has a distinct net charge is disclosed. 'Ananain' and 'comosain' are such enzymes, which may be distinguished by their specificities for certain synthetic substrates. A process for the production thereof is also disclosed which comprises separation from pineapple plant material and purification. Such enzymes may be used in the debridement of eschar tissues.

Growing community of inventors

Cambridgeshire, United Kingdom

David J Buttle